Literature DB >> 14661176

Comparison of wild-type and class I integrase mutant-FIV vectors in retina demonstrates sustained expression of integrated transgenes in retinal pigment epithelium.

Nils Loewen1, David A Leske, Yi Chen, Wu-Lin Teo, Dyana T Saenz, Mary Peretz, Jonathan M Holmes, Eric M Poeschla.   

Abstract

BACKGROUND: In neonatal and adult rodent retina, substantial lentiviral vector expression has been detected primarily in retinal pigment epithelium (RPE), except in very young animals (2-5 days post-natal). In non-retinal tissues, studies of lentiviral vectors have utilized various controls. Among the most stringent are class I integrase mutants, which selectively block the integration reaction while leaving all other gag/pol-encoded functions intact. For HIV-1 vectors injected into brain, these have been used to simultaneously control for pseudotransduction and verify that long-term expression requires integration. Such experiments compare particles that differ only in a single amino acid within a single enzyme that forms a very small molar fraction of the virion. Class I integrase mutants have not been described for feline immunodeficiency virus (FIV) integrase, or tested in the eye for any lentiviral vector.
METHODS: We compared subretinally and intravitreally injected FIV vectors and followed animals for up to 7 months, a duration that exceeds prior studies. We also compared the wild-type (WT) vector with one incorporating a single class I amino acid mutation in FIV integrase (D66V). A mock vector (packaging construct absent) was an alternative control. All vectors were vesicular stomatitis virus glycoprotein G (VSV-G)-pseudotyped and were injected on day 7 of life. One group of animals received either subretinal or intravitreal injections of WT vector in the right eyes. Control left eyes were injected with mock vector. These animals were sacrificed at 2 or 7 days post-injection. A second group received subretinal injections of either WT vector or equivalent D66V vector (reverse transcriptase-normalized to WT), and were analyzed after 2, 3 and 7 months. All eyes were scored for marker gene (beta-galactosidase) expression by an observer blinded to vector assignments.
RESULTS: Subretinal FIV vector injections were much more effective than intravitreal injections. The RPE was the principal retinal layer transduced by the WT vector, and at least 50% of the area of the retina expressed the marker gene at 3 and 7 months. Occasional cells in inner retinal layers also expressed beta-galactosidase at these time points. The sustained retinal expression produced by subretinally injected vector was blocked by the D66V mutation.
CONCLUSIONS: These results show that class I integrase mutant FIV vectors are useful control vectors, and that VSV-G-pseudotyped FIV vectors produce extensive retinal expression for at least 215 days, the longest duration yet reported for lentiviral vectors in retina. Transgene expression is mostly restricted to RPE after post-natal day 7 in rats, suggesting that FIV vectors could be used to target RPE for gene therapy. Copyright 2003 John Wiley & Sons, Ltd.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14661176     DOI: 10.1002/jgm.447

Source DB:  PubMed          Journal:  J Gene Med        ISSN: 1099-498X            Impact factor:   4.565


  16 in total

1.  Lentiviral vectors with a defective integrase allow efficient and sustained transgene expression in vitro and in vivo.

Authors:  Stéphanie Philippe; Chamsy Sarkis; Martine Barkats; Hamid Mammeri; Charline Ladroue; Caroline Petit; Jacques Mallet; Che Serguera
Journal:  Proc Natl Acad Sci U S A       Date:  2006-11-09       Impact factor: 11.205

Review 2.  Integration-deficient lentiviral vectors: a slow coming of age.

Authors:  Klaus Wanisch; Rafael J Yáñez-Muñoz
Journal:  Mol Ther       Date:  2009-06-02       Impact factor: 11.454

3.  Prolonged transgene expression with lentiviral vectors in the aqueous humor outflow pathway of nonhuman primates.

Authors:  Román A Barraza; Carol A Rasmussen; Nils Loewen; J Douglas Cameron; B'Ann T Gabelt; Wu-Lin Teo; Paul L Kaufman; Eric M Poeschla
Journal:  Hum Gene Ther       Date:  2009-03       Impact factor: 5.695

4.  Cell culture processes for the production of viral vectors for gene therapy purposes.

Authors:  James N Warnock; Otto-Wilhelm Merten; Mohamed Al-Rubeai
Journal:  Cytotechnology       Date:  2006-06-30       Impact factor: 2.058

Review 5.  Lentiviral vector-mediated RNA silencing in the central nervous system.

Authors:  Thomas H Hutson; Edmund Foster; Lawrence D F Moon; Rafael J Yáñez-Muñoz
Journal:  Hum Gene Ther Methods       Date:  2013-11-01       Impact factor: 2.396

Review 6.  Viral vectors: from virology to transgene expression.

Authors:  D Bouard; D Alazard-Dany; F-L Cosset
Journal:  Br J Pharmacol       Date:  2009-05       Impact factor: 8.739

7.  Histone deacetylase inhibition activates transgene expression from integration-defective lentiviral vectors in dividing and non-dividing cells.

Authors:  Laetitia P L Pelascini; Josephine M Janssen; Manuel A F V Gonçalves
Journal:  Hum Gene Ther       Date:  2012-12-11       Impact factor: 5.695

8.  Efficient gene transfer to retinal pigment epithelium cells with long-term expression.

Authors:  Lingyun Cheng; Mitsuko Toyoguchi; David J Looney; Jeffery Lee; Marie C Davidson; William R Freeman
Journal:  Retina       Date:  2005 Feb-Mar       Impact factor: 4.256

Review 9.  Human gene therapy vectors derived from feline lentiviruses.

Authors:  Román A Barraza; Eric M Poeschla
Journal:  Vet Immunol Immunopathol       Date:  2008-01-19       Impact factor: 2.046

Review 10.  Gene transfer to the outflow tract.

Authors:  Yalong Dang; Ralitsa Loewen; Hardik A Parikh; Pritha Roy; Nils A Loewen
Journal:  Exp Eye Res       Date:  2016-04-27       Impact factor: 3.467

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.